Randomized multicenter phase II study of flavopiridol alvocidib

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia by Joshua F. Zeidner, Matthew C. Foster, Amanda L. Blackford, Mark R. Litzow, Lawrence E. Morris, Stephen A. Strickland, Jeffrey E. Lancet, Prithviraj Bose, M. Yair Levy, Raoul Tibes, Ivana Gojo, Christopher D. Gocke, Gary L. Rosner, Richard F. Little, John J. Wright, L. Austin Doyle, B. Douglas Smith, and Judith E. Karp haematol Volume 100(9): 1172 -1179 September 4, 2015 © 2015 by Ferrata Storti Foundation

Consort Diagram. 172 patients were randomized between FLAM (n = 114) and 7+3 (n = 58), 109 patients on FLAM and 56 patients on 7+3 were analyzed for response and overall survival (OS). 1 2 patients did not receive FLAM after randomization: progressive deteri. . . Joshua F. Zeidner et al. Haematologica 2015; 100: 1172 -1179 © 2015 by Ferrata Storti Foundation

Patients’ characteristics. Joshua F. Zeidner et al. Haematologica 2015; 100: 1172 -1179 © 2015 by Ferrata Storti Foundation

Toxicity comparisons. Joshua F. Zeidner et al. Haematologica 2015; 100: 1172 -1179 © 2015 by Ferrata Storti Foundation

Response comparisons. Joshua F. Zeidner et al. Haematologica 2015; 100: 1172 -1179 © 2015 by Ferrata Storti Foundation

Day 14 bone marrow biopsy comparisons. Joshua F. Zeidner et al. Haematologica 2015; 100: 1172 -1179 © 2015 by Ferrata Storti Foundation

Subset analyses. Joshua F. Zeidner et al. Haematologica 2015; 100: 1172 -1179 © 2015 by Ferrata Storti Foundation

Kaplan-Meier estimates of overall survival (OS) and event-free survival (EFS). Joshua F. Zeidner et al. Haematologica 2015; 100: 1172 -1179 © 2015 by Ferrata Storti Foundation